<?xml version="1.0" encoding="UTF-8"?>
<ref id="bb0405">
 <label>81</label>
 <element-citation publication-type="journal" id="rf0375">
  <person-group person-group-type="author">
   <name>
    <surname>Madelain</surname>
    <given-names>V.</given-names>
   </name>
   <name>
    <surname>Nguyen</surname>
    <given-names>T.H.T.</given-names>
   </name>
   <name>
    <surname>Olivo</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>de Lamballerie</surname>
    <given-names>X.</given-names>
   </name>
   <name>
    <surname>Guedj</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Taburet</surname>
    <given-names>A.-M.</given-names>
   </name>
   <name>
    <surname>Mentr√©</surname>
    <given-names>F.</given-names>
   </name>
  </person-group>
  <article-title>Ebola virus infection: review of the pharmacokinetic and pharmacodynamic properties of drugs considered for testing in human efficacy trials</article-title>
  <source>Clin. Pharmacokinet.</source>
  <volume>55</volume>
  <year>2016</year>
  <fpage>907</fpage>
  <lpage>923</lpage>
  <pub-id pub-id-type="doi">10.1007/s40262-015-0364-1</pub-id>
  <pub-id pub-id-type="pmid">26798032</pub-id>
 </element-citation>
</ref>
